Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹17 Cr
P/E Ratio
--
P/B Ratio
-13.91
Industry P/E
55.6
Debt to Equity
83.26
ROE
-281.14 %
ROCE
-59.88 %
Div. Yield
0 %
Book Value
-3.31
EPS
-5.48
CFO
₹11.48 Cr
EBITDA
₹8.71 Cr
Net Profit
₹-4.47 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Parmax Pharma
| 3.91 | 5.12 | 15.61 | 57.90 | 3.06 | 24.59 | -- |
|
BSE Commodities
| 3.84 | 2.25 | 4.59 | 6.16 | 7.95 | 29.19 | -- |
|
BSE Small Cap
| -10.08 | 4.17 | -3.87 | 5.97 | 18.98 | 35.50 | 15.85 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Parmax Pharma
| 36.32 | -15.84 | -35.45 | 110.95 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 |
|
BSE Commodities
| 8.14 | 17.51 | 1.22 | 61.53 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 834.05 | 11,051.40 | 103.58 | -- | |
| 4.68 | 61.02 | 77.64 | 54.45 | |
| 680.05 | 10,831.91 | 52.49 | 7.43 | |
| 239.85 | 76.23 | 12.89 | 17.15 |
No Review & Analysis are available.
Manufacture of allopathic pharmaceutical preparations
Incorporated
1994
Chairman
--
Managing Director
Umang A Gosalia
Headquarters
Rajkot, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Parmax Pharma Ltd stood at ₹ 15 Cr as on 31-Dec-24
The share price of Parmax Pharma Ltd is ₹45.98 (BSE) as of 24-Apr-2025 IST. Parmax Pharma Ltd has given a return of 3.06% in the last 3 years.
Parmax Pharma Ltd has a market capitalisation of ₹ 17 Cr as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Parmax Pharma Ltd is -13.91 times as on 24-Apr-2025, a 219% discount to its peers’ median range of 11.68 times.
Since, TTM earnings of Parmax Pharma Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Parmax Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Parmax Pharma Ltd.
Manufacture of allopathic pharmaceutical preparations
The promoters of Parmax Pharma Ltd are ALKESH MAHASUKH GOPANI and VIPUL MAHASUKHLAL GOPANI. They collectively own 30.79 per cent of the total equity. The chairman of the company is
There is no promoter pledging in Parmax Pharma Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
76
|
|
|
61
|
|
|
10,988
|
|
|
10,551
|
| Parmax Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-5.77
|
|
Net Margin(%)
|
-7.37
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Parmax Pharma Ltd was ₹-2 Cr.
₹0.98
(
